NDLI: Insomnia: Zolpidem Extended-Release for the Treatment of Sleep Induction and Sleep Maintenance Symptoms

Please wait, while we are loading the content...

Assessing the Effectiveness of Informational Video Clips on Iranian Immigrants' Attitudes Toward and Intention to Use the BC HealthGuide Program in the Greater Vancouver Area

Every Clinician Deserves an Un-Sales Rep

Guidelines and Rules: Friend or Foe?

Studies on Parasitologic and Haematologic Activities of an Enaminone Derivative of 4-Hydroxyquinolin-2(1H)-one Against Murine Schistosomiasis Mansoni

Aggressive Angiomyxoma of the Vulva in Pregnancy: A Case Report and Review of Management Options

Readers Respond to “Advanced Practice Nurses Say ‘No’ to a Mandatory Doctor of Nursing Practice Degree”

Author's Reply to Readers' Responses to “Advanced Practice Nurses Say 'No' to a Mandatory Doctor of Nursing Practice Degree”

Whatever Happened to Plausibility as the Basis for Clinical Research and Practice After EBM and CAM Rushed in?

It Is Time to Extend the Laboratory Critical (Panic) Value System to Include Vital Values

Case 15: When a Stroke Is Not a Stroke

Bupropion Normalizes Cognitive Performance in Patients With Depression

Online Health Research Is Widespread, but Few Check the Source and Date

Evaluation of Possible Gastrinoma

Paroxysmal Hemidyskinesia Related to a Large Thalamic Cyst

Biomedical Entrepreneurship Should Be the Fourth Mission of All Healthcare Organizations

Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death: Considerable Costs and Limited Benefits

Small Bowel Bezoar in a Patient With Noonan Syndrome: Report of a Case

California and Universal Health Coverage

The Biopsychosocial Information Model: The New Disease Paradigm

Are Various Babesia Species a Missed Cause for Hypereosinophilia? A Follow-up on the First Reported Case of Imatinib Mesylate for Idiopathic Hypereosinophilia

Reader's Response to “Rapid and Complete Control of Idiopathic Hypereosinophilia With Imatinib Mesylate”

Pay, Pride, and Public Purpose: Why America's Doctors Should Support Universal Healthcare

Healthcare Systems and Motivation

What You Don't Know Can Hurt Your Patients

White Coat Hypertension: Relevance to Clinical and Emergency Medical Services Personnel

Healthcare and the Hospital Chaplain

Carotid Screening Guidelines – Overvalued

Extraintestinal Manifestations of Inflammatory Bowel Disease: Focus on the Musculoskeletal, Dermatologic, and Ocular Manifestations

About Intercessory Prayer: The Scientific Study of Miracles

Resource Allocation in Healthcare: Implications of Models of Medicine as a Profession

HIV Care at a Crossroads: The Emerging Crisis in the US HIV Epidemic

To Be a Great Physician, You Must Understand the Whole Story

Dietary Factors in the Modulation of Inflammatory Bowel Disease Activity

Born in the USA: How a Broken Maternity System Must Be Fixed to Put Women and Children First

Improving Laboratory Testing to Save Lives in Resource-Limited Settings, With a Particular Focus on HIV/AIDS: Humanitarian Efforts by the ASCP

Year: 2006, Volume: 8

Year: 2005, Volume: 7

Year: 2005, Volume: 6

Year: 2004, Volume: 6

Insomnia: Zolpidem Extended-Release for the Treatment of Sleep Induction and Sleep Maintenance Symptoms

Content Provider	PubMed Central
Author	Doghramji, Paul P.
Copyright Year	2007
Abstract	Insomnia impairs daytime functioning or causes clinically significant daytime distress. The consequences of insomnia, if left untreated, may contribute to the risks of developing additional serious conditions, such as psychiatric illness, cardiovascular disease, or metabolic issues. Furthermore, some comorbidities associated with insomnia may be bidirectional in their causality because psychiatric and other medical problems can increase the risk for insomnia. Regardless of the serious consequences of inadequately treated insomnia, clinicians often do not inquire into their patients' sleep habits, and patients, in turn, are not forthcoming with details of their sleep difficulties. The continuing education of physicians and patients with regard to insomnia and currently available therapies for the treatment of insomnia is, therefore, essential. Insomnia may present as either a difficulty falling asleep, difficulty maintaining sleep, or waking too early without being able to return to sleep. Furthermore, these symptoms often change over time in an unpredictable manner. Therefore, when considering a sleep medication, one with efficacy for the treatment of multiple insomnia symptoms is recommended. A modified-release formulation of zolpidem, zolpidem extended-release, has been approved for the treatment of insomnia characterized by both difficulty in falling asleep and maintaining sleep. Here, we review studies supporting the use of zolpidem extended-release in the treatment of sleep-onset and sleep maintenance difficulties.
Starting Page	11
File Format	PDF
ISSN	15310132
e-ISSN	15310132
Journal	Medscape General Medicine
Issue Number	1
Volume Number	9
Language	English
Publisher	Medscape
Publisher Date	2007-01-17
Access Restriction	Open
Rights Holder	Medscape
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties.

Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance.

Randomized, double blind trial of Zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice

Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes

Zolpidem modified-release in insomnia

Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

Evaluation of Automated and Semi-Automated Scoring of Polysomnographic Recordings from a Clinical Trial Using Zolpidem in the Treatment of Insomnia

Sleep Duration and Insomnia in Adolescents Seeking Treatment for Anxiety in Primary Health Care

Eszopiclone and Zolpidem Produce Opposite Effects on Hippocampal Ripple Density

Insomnia: Zolpidem Extended-Release for the Treatment of Sleep Induction and Sleep Maintenance Symptoms

Similar Documents

Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties.

Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance.

Randomized, double blind trial of Zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice

Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes

Zolpidem modified-release in insomnia

Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

Evaluation of Automated and Semi-Automated Scoring of Polysomnographic Recordings from a Clinical Trial Using Zolpidem in the Treatment of Insomnia

Sleep Duration and Insomnia in Adolescents Seeking Treatment for Anxiety in Primary Health Care

Eszopiclone and Zolpidem Produce Opposite Effects on Hippocampal Ripple Density

Insomnia: Zolpidem Extended-Release for the Treatment of Sleep Induction and Sleep Maintenance Symptoms